Compare TVRD & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVRD | CNF |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | China |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 27.2M |
| IPO Year | N/A | 2018 |
| Metric | TVRD | CNF |
|---|---|---|
| Price | $3.09 | $2.85 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | ★ 49.0K | 2.8K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $0.37 |
| 52 Week High | $43.65 | $24.00 |
| Indicator | TVRD | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 35.75 |
| Support Level | $2.75 | $2.72 |
| Resistance Level | $3.50 | $5.13 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 45.33 | 25.87 |
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.